Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: IMPACT Therapeutics, Inc

Market Cap 8.89B 10.29B 1.31B 1.15B 1.06B 990M 1.86B 124B 1.87B 12.61B 4.9B 60.98B 4.93B 4.82B 212B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 8.06B 9.33B 1.19B 1.04B 961M 897M 1.68B 112B 1.7B 11.43B 4.45B 55.27B 4.47B 4.37B 192B EV / Sales 2026 *
29x
EV / Sales 2027 * 8.09x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-2.74%
1 week-3.36%
Current month-9.17%
1 month-5.58%
1 week 35.58
Extreme 35.58
37.68
1 month 35
Extreme 35
43.08
Current year 28.2
Extreme 28.2
47.98
1 year 28.2
Extreme 28.2
47.98
3 years 28.2
Extreme 28.2
47.98
5 years 28.2
Extreme 28.2
47.98
10 years 28.2
Extreme 28.2
47.98
Manager TitleAgeSince
Chief Executive Officer 69 31/05/2014
Director of Finance/CFO 51 30/04/2024
Chief Tech/Sci/R&D Officer 44 31/12/2024
Director TitleAgeSince
Director/Board Member 69 22/09/2025
Director/Board Member 69 31/05/2014
Director/Board Member 55 22/09/2025
Change 5-day change 1-year change 3-year change Capi.($)
-2.74%-3.36% - - 1.31B
+2.44%+3.56%-8.73%-3.36% 43.24B
+1.73%+3.59%+318.08%+564.04% 35.25B
+0.61%+1.34%+10.00%+46.20% 30.22B
+0.02%-5.93%+8.45%-21.44% 28.01B
-1.06%-3.71%+9.08%+19.56% 24.08B
-1.23%+2.11% - - 14.16B
-0.99%-2.53%+47.29%+102.88% 13.01B
+2.58%+3.83%+9.41%+15.09% 12.7B
+2.39%+2.61%+102.86%+84.20% 12.54B
Average +0.38%-0.14%+62.06%+100.89% 21.45B
Weighted average by Cap. +0.88%-0.19%+68.41%+118.52%

Financials

2026 *2027 *
Net sales 278M 321M 40.97M 35.8M 33.12M 30.91M 58.03M 3.87B 58.45M 394M 153M 1.9B 154M 151M 6.61B 941M 1.09B 139M 121M 112M 105M 197M 13.13B 198M 1.33B 519M 6.46B 522M 510M 22.43B
Net income - -
Net Debt -832M -963M -123M -107M -99.32M -92.7M -174M -11.61B -175M -1.18B -459M -5.71B -461M -451M -19.83B -1.28B -1.48B -189M -165M -152M -142M -267M -17.82B -269M -1.81B -705M -8.76B -708M -693M -30.44B
Logo IMPACT Therapeutics, Inc
IMPACT Therapeutics Inc is a China-based company mainly engaged in biotechnology research and commercialization. The Company is in the commercialization stage. The Company is committed to advancing synthetic lethality (SL)-based precision anti-cancer therapies globally. The Company's independently developed core product, senaparib, in China as a 1L maintenance therapy for ovarian cancer (OC). The Company is currently developing product pipeline packages such as PARP1/2, PARP1, ATR, WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2.
Employees
-
Date Price Change Volume
23/06/26 HK$36.24 -2.74% 173,200
22/06/26 HK$37.26 +0.70% 357,800
18/06/26 HK$37.00 -1.80% 252,200
17/06/26 HK$37.68 +0.48% 203,400
16/06/26 HK$37.50 +1.68% 188,400
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
32.19CNY
Average target price
32.43CNY
Spread / Average Target
+0.74%

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 7630 Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!